The recent surge in capital into specialized pharmaceutical companies, particularly those focusing on groundbreaking therapies and complex drug development programs, has fueled what some are calling "High Stakeholder Pharma." While the promise for revolutionary treatments and substantial returns is undeniable, the connected risks are also considera